In this study, a synthetic vitamin D analog, paricalcitol was used to induce the expression of JMJD3 in cancer cells to explore the mechanism underlying the effect of JMJD3 in vivo and evaluate its utility for clinical tumor therapy. This evidence concerns the gene KDM6B and neoplasm.